Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Disentangling the reasons why older adults do not readily participate in cancer trials: a socio-epidemiological mixed methods approach.
Hagège M, Bringuier M, Martinez-Tapia C, Chouaïd C, Helissey C, Brain E, Lempdes GR, Dubot C, Bello-Roufai D, Geiss R, Kempf E, Gourden A, Elgharbi H, Garrigou S, Gregoire L, Derbez B, Canouï-Poitrine F. Hagège M, et al. Among authors: chouaid c. Age Ageing. 2024 Feb 1;53(2):afae007. doi: 10.1093/ageing/afae007. Age Ageing. 2024. PMID: 38346934 Free PMC article.
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R.
Filippi AR, Bar J, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido P, Haakensen VD, Kao S, Markman B, McDonald F, Mornex F, Moskovitz M, Peters S, Sibille A, Siva S, van den Heuvel M, Vercauter P, Anand S, Chander P, Licour M, de Lima AR, Qiao Y, Girard N. Filippi AR, et al. Among authors: chouaid c. ESMO Open. 2024 Jun 3;9(6):103464. doi: 10.1016/j.esmoop.2024.103464. Online ahead of print. ESMO Open. 2024. PMID: 38833971
Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort.
Thomas QD, Quantin X, Lemercier P, Chouaid C, Schneider S, Filleron T, Remon-Masip J, Perol M, Debieuvre D, Audigier-Valette C, Justeau G, Loeb A, Hiret S, Clement-Duchene C, Dansin E, Stancu A, Pichon E, Bosquet L, Girard N, Du Rusquec P. Thomas QD, et al. Among authors: chouaid c. ESMO Open. 2024 Jun 3;9(6):103473. doi: 10.1016/j.esmoop.2024.103473. Online ahead of print. ESMO Open. 2024. PMID: 38833966
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study).
Amari L, Tomasini P, Dantony E, Rousseau-Bussac G, Ricordel C, Bigay-Game L, Arpin D, Morel H, Veillon R, Justeau G, Huchot E, Fournel P, Vergnenegre A, Bizeux A, Subtil F, Clarisse B, Decroisette C, Chouaid C, Greillier L, Bylicki O. Amari L, et al. Among authors: chouaid c. Lung Cancer. 2024 May 31;193:107843. doi: 10.1016/j.lungcan.2024.107843. Online ahead of print. Lung Cancer. 2024. PMID: 38830303
393 results